Table 3.
Subgroup analysis for risk of cardiovascular adverse events before and after methylphenidate according to congenital heart disease and daily dose
| Risk period | Arrhythmias | Hypertension | Myocardial infarction | Ischemic stroke | Heart failure | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | |||||
| Congenital heart disease | ||||||||||||||
| Yes | 46 | 3.49 (2.33 to 5.22) | 31 | 0.95 (0.58 to 1.56) | 3 | NA | 2 | NA | 7 | NA | ||||
| No | 818 | 1.34 (1.23 to 1.46) | 365 | 0.99 (0.87 to 1.13) | 49 | 1.36 (0.89 to 2.07 | 65 | 0.61 (0.42 to 0.89) | 37 | 0.38 (0.20 to 0.72) | ||||
| Daily dose (mg) | ||||||||||||||
| Low (<27) | 814 | 1.42 (1.29 to 1.56) | 375 | 1.03 (0.88 to 1.20) | 51 | 1.49 (0.97 to 2.30) | 66 | 0.93 (0.62 to 1.38) | 40 | 0.18 (0.07 to 0.46) | ||||
| High (≥27) | 622 | 1.42 (1.29 to 1.55) | 285 | 1.04 (0.91 to 1.19) | 30 | 1.39 (0.88 to 2.20) | 34 | 0.27 (0.15 to 0.49) | 26 | 1.06 (0.56 to 2.02) | ||||
NA=not applicable.
*Rate ratio adjusted for age, comorbidity, and co-medication in time varying method.
†Case series analysis according to daily dose conducted in dataset of patients with prescriptions <27mg of daily dose, and those with prescriptions ≥27 mg. Patient can be duplicated in both dataset as they might change their dose in study period.